Page last updated: 2024-10-15

vicine

Description

vicine: pyrimidine glycoside found in fava bean; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135413566
CHEBI ID9976
SCHEMBL ID627098
SCHEMBL ID21772181
MeSH IDM0054542

Synonyms (38)

Synonym
vicioside
nsc-95092
152-93-2
C08437 ,
vicine
2,6-diamino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrimidin-4-one
divicine, 5-beta-d-glucopyranoside (van)
vicine (van)
2,6-diamino-5-(beta-d-glucopyranosyloxy)-4(1h)-pyrimidinone
nsc 95092
glucopyranoside, divicine-5, beta-d-
col14pjw3x ,
einecs 205-809-4
4(1h)-pyrimidinone, 2,6-diamino-5-(beta-d-glucopyranosyloxy)-
unii-col14pjw3x
divicine 5-glucoside
vicine [mi]
2,6-diamino-5-(.beta.-d-glucopyranosyloxy)-4(1h)-pyrimidinone
divicine-.beta.-glucoside
SCHEMBL627098
2,6-diamino-5-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)pyrimidin-4(3h)-one
CHEBI:9976
surecn627098
vicine, analytical standard
2,6-diamino-5-(beta-d-glucopyranosyloxy)-4-pyrimidinone
SCHEMBL21772181
AKOS037515256
DTXSID80876124
2,6-diamino-4-hydroxy-5-pyrimidinyl beta-d-glucopyranoside
Q5961382
2,4-diamino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrimidin-6-one
CS-0018598
HY-N2093
cid 91446
MS-24389
2,6-diamino-5-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)pyrimidin-4(1h)-one
A848550
E80552

Research Excerpts

Overview

Vicine is a glucoside from broad beans (Vicia faba) It is hydrolyzed upon ingestion to the unstable aglycon divicine. Autoxidation has been implicated in the onset of hemolysis in favism.

ExcerptReference
"Vicine is a glucoside from broad beans (Vicia faba) that is hydrolyzed upon ingestion to the unstable aglycon divicine, the autoxidation of which has been implicated in the onset of hemolysis in favism,possibly via production of superoxide and hydrogen peroxide. "( Electron spin resonance characterization of the radicals produced by enzymatic or chemical cleavage of vicine.
Musci, G; Pedersen, JZ; Rotilio, G, 1988
)
"Divicine is an unstable aglycon metabolite of the fava bean pyrimidine beta-glucoside vicine. "( Chemical analysis and hemolytic activity of the fava bean aglycon divicine.
Jollow, DJ; McMillan, DC; Meier, GP; Schey, KL,
)

Bioavailability

ExcerptReference
"This study in the rat established the effects that a broad-spectrum and poorly absorbed antibiotic, neomycin sulfate, had on the in vitro and in vivo hydrolysis of vicine and convicine by the intestinal microflora, and on vicine- and convicine-induced depletion of blood glutathione and the resulting toxicity."( Effect of neomycin on the hydrolysis and toxicity of vicine and convicine in rats.
Arbid, MS; Frohlich, AA; Madhyastha, MS; Marquardt, RR, 1993
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (37.25)18.7374
1990's9 (17.65)18.2507
2000's5 (9.80)29.6817
2010's15 (29.41)24.3611
2020's3 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (98.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]